On Thursday, Uganda confirmed an outbreak of the Ebola virus in its capital city Kampala, with the first confirmed patient dying from it a day before. As per the new developments, the officials are now preparing to deploy a trial vaccine to put an end to this outbreak.
Groups of scientists are working on the vaccine and deployment of more than 2,000 doses of a candidate vaccine against the Sudan strain of Ebola has been planned and confirmed by the Uganda Virus Research Institute. As per the World Health Organization (WHO), Uganda has access to 2,169 doses of trial vaccine. For now, however, there are no approved vaccines for the strain and officials are still investigating the source of the outbreak.
The WHO had also allocated $1 million from its contingency fund for emergencies to support quick action and contain the outbreak in the country.
On Wednesday, the Sudan strain of Ebola killed a nurse employed at Kampala's main referral hospital. It is after his death that Ebola was declared an outbreak in the country. Post-mortem samples too have confirmed the Sudan Ebola Virus Disease and at least 44 contacts of the deceased man have been listed for tracing. 30 of these are health workers.
Ebola is a highly infectious hemorrhagic fever, which is transmitted through contact with bodily fluids and tissue. Symptoms include headache, vomiting of blood, muscle pains and bleeding.
it was in the late 2022, when Uganda had last suffered an Ebola outbreak. It killed 55 of the 143 people who were infected and was declared over on January 11, 2023.
As per the WHO, Ebola virus disease (EVD) is a rare but severe illness in humans and is often fatal. People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person such as saliva, urine, faeces or semen, or things that have body fluids of an infected person like clothes or sheets.
Ebola enters the body through cuts in the skin or when one is touching their eyes, nose or mouth. Early symptoms include fever, fatigue and headache.
It was first discovered in 1976 in two simultaneous outbreak, when in Nzara, South Sudan and other in Yambuku, Democratic Republic of Congo. The latter occurred near a village near the Ebola River, which is where it gets its name from.
It is highly infectious and transmissible disease, in fact, there have been cases of health-care workers who have frequently been infected while treating patients with suspected or confirmed Ebola. This occurs through close contact with patients when infection control precautions are not practiced strictly.
Cases of people conducted burial ceremonies, involving direct contact with the body of the deceased too can lead to the transmission of Ebola. Even after the long suffering and recovery, there is a possibility of sexual transmission. Pregnant women who get acute Ebola and recover may still carry the virus in their breastmilk, or in pregnancy related fluids and tissues.
Credit: iStock
The death toll from Ebola has crossed 2,000 in the Democratic Republic of the Congo (DRC), three months after the outbreak was officially declared in May.
The outbreak has caused 4,381 confirmed cases across five provinces, making it the fastest-growing Ebola outbreak recorded in the Central African country. The response has been complicated by strikes by unpaid health workers, misinformation and cultural practices.
The outbreak is caused by the rare Bundibugyo strain of Ebola, for which there is currently no approved treatment or vaccine.
According to the World Health Organization (WHO), the virus first emerged in the DRC in February, about three months before the outbreak was officially declared in the DRC and neighboring Uganda on May 15.
Some early patients were reportedly treated for malaria or typhoid, which can initially cause fever, weakness, vomiting and diarrhea. Early testing also focused on the more common Zaire strain of Ebola, delaying recognition of the Bundibugyo virus.
By early May, WHO had identified an unusual cluster of severe illness and deaths in the Mongbwalu health zone in Ituri Province. An investigation covering April 15 to May 13 subsequently identified 246 suspected cases and 65 deaths across three health zones.
The response has also been affected by conditions in Ituri, including armed conflict, population displacement and poor road access. Health workers have faced shortages of protective equipment, while some healthcare facilities have been affected by workers' strikes.
A new study published in Nature Medicine suggests that the outbreak began through a zoonotic spillover event, meaning the virus jumped from animals to humans before spreading between people.
Researchers from Congo, Uganda, Belgium and other countries found that the outbreak strain was genetically distinct from Bundibugyo Ebola viruses identified during previous outbreaks in 2007 and 2012.
The findings are consistent with a new animal-to-human transmission event, followed by sustained human-to-human transmission.
The study did not identify the specific animal source. However, Ebola viruses are known to periodically spill over from infected animals into human populations.
Genetic analysis also confirmed that cases detected in Uganda were linked to the outbreak in Congo.
Bundibugyo virus disease (BVD) outbreaks were previously recorded in 2007–2008 in Bundibugyo District, Uganda, and in 2012 in Isiro, DRC.
For the 2026 outbreak, researchers generated 22 viral genomes from samples collected from patients with BVD in the DRC and Uganda.
The genomes formed a well-supported phylogenetic cluster separate from variants associated with the 2007 and 2012 outbreaks. The analysis also showed evidence of sustained human-to-human transmission.
The researchers called for greater decentralized laboratory diagnostic capacity, including pan-Orthoebolavirus testing and genomic sequencing, to improve early detection and control of future outbreaks.
Ebola can jump to humans from infected animals such as bats, monkeys and apes. Transmission can occur through contact with blood, body fluids, excrement or raw meat during hunting and butchering.
Once the virus enters the human population, it can spread from person to person through contact with infected bodily fluids.
Symptoms of Bundibugyo virus disease are similar to those caused by other Ebola viruses and can include:
Credit: AI
What if one blood sample could detect symptoms of multiple cancers at once, while also disclosing which organ may be affected? A new study from UCLA has brought that possibility a step closer to reality.
Researchers have at UCLA have developed a blood test called MethylScan that can detect molecular signals linked to multiple cancers and other diseases by analysing DNA fragments circulating in the bloodstream.
The findings, published in the Proceedings of the National Academy of Sciences, suggest the test could offer a simpler and potentially cheaper way to screen for serious diseases like cancer before their symptoms appear.
A blood test may be able to detect multiple cancers at once due to cell-free DNA (cfDNA). Every day, billions of cells die and release tiny fragments of DNA into the bloodstream. These fragments carry information about where they came from and what is happening in that tissue.
Instead of primarily searching for cancer-causing mutations, MethylScan looks at DNA methylation, a type of chemical tags that regulate how genes behave.
Different organs have distinct methylation patterns, and those patterns can change when cells become cancerous or diseased.
“DNA methylation reflects the health status of a tissue. It’s a very informative signal,” said Dr Wenyuan Li, professor of pathology and laboratory medicine at UCLA.
The researchers also developed a method to filter out the DNA released by normal blood cells, reducing the "background noise” that can make early cancer signals difficult to detect.
The researchers tested MethylScan using blood samples from 1,061 people, including patients with liver, lung, ovarian and stomach cancers, people with liver diseases and healthy participants.
At 98% specificity, the test detected about 63% of cancers across all stages. For early-stage cancers, its sensitivity was around 55%.
The test also showed promise in identifying where an abnormal signal originated. This could help as a positive blood test would still need to be followed by imaging or other diagnostic tests.
“Being able to trace signals back to their source is important because a positive blood test needs to be followed by imaging or other diagnostic procedures directed at the right organ,” Li said.
Also read: Tudriqev: US FDA Approves Replimune's Skin Cancer Drug After Rejecting It Twice
“Early detection is crucial,” said Dr Jasmine Zhou, the study’s senior author. “Survival rates are far higher when cancers are caught before they spread.”
The findings are promising, but larger trials will be needed to establish whether such tests can reliably detect cancers in people who have no symptoms.
Also read: Following A Western Diet? Changes In Your Gut Bacteria Could Increase Colon Cancer Risk
The findings come as another multi-cancer test, Galleri, is designed to detect signals from more than 50 cancers from a single blood sample.
Reuters reported this month that the US FDA plans to convene an advisory panel in September to review its application for approval.
But experts continue to stress that these tests are not replacements for established screening, such as mammograms or colonoscopies.
Credit: AP Photo
US President Donald Trump has signed an executive order aimed at changing childhood vaccine recommendations, including moving toward separating the measles, mumps and rubella (MMR) vaccine into individual shots.
The executive order, titled “Delivering Gold Standard Childhood Vaccine Recommendations for Americans,” has sparked debate over how childhood vaccines should be administered and whether combination vaccines should instead be given separately.
Amid criticism of the move, HealthandMe spoke to public health experts to understand whether splitting the MMR vaccine offers any proven health benefit and what it could mean for children and vaccination coverage.
Dr. Sabine Kapasi, Global Health Strategist and a UN Advisor, told HealthandMe that combination vaccines are more than a matter of convenience.
“Combination vaccines are not simply a matter of convenience. They can reduce the number of injections and healthcare visits required, support timely vaccination and help health systems reach children who may otherwise be missed,” she said.
“The more fragmented the pathway becomes, the more important it is to understand its impact on uptake, completion and equity,” Dr. Sabine added.
Dr. Rajeev Jayadevan, former President of IMA Cochin and Convener of the Research Cell, Kerala, also highlighted the practical disadvantage of requiring parents to make additional clinic visits when vaccines that can be administered together are separated.
There is currently no adequate scientific validation for the argument that giving the MMR components separately is inherently healthier, according to Dr. Rajeev.
“The argument that splitting the shots is a healthier option does not have adequate scientific validation, because the body’s immune system routinely encounters numerous antigens simultaneously and effectively in everyday life,” he told HealthandMe.
Dr. Sabine emphasized that any change to childhood immunization policy should be based on evidence rather than simply altering an established schedule.
“Any change to childhood immunization policy should therefore be grounded in transparent evidence, rigorous safety and effectiveness assessment, and real-world data on vaccination coverage and completion,” she added.
Separating combination vaccines could make vaccination more cumbersome for families by requiring additional visits.
Dr. Sabine said vaccination programs operate within different health systems, meaning even small changes in scheduling can have implications for access, logistics, costs and continuity of care.
“The priority should remain consistent: designing immunization systems that are evidence-led, accessible and resilient enough to protect children across populations—not simply changing the schedule for the sake of changing it,” she said.
In a post on X US Senator Bill Cassidy, a physician, also criticized the executive order and warned that breaking up combination vaccines could mean children need more shots to receive the same protection.
“It will increase hesitancy and make children less safe,” he said, urging parents to discuss vaccination decisions with their child’s pediatrician.
Former White House COVID-19 Response Coordinator Dr. Ashish Jha said European countries do not routinely split the MMR vaccine into three separate shots. “No European country splits the MMR vaccine as 3 separate shots,” he said in a post on X.
He added that Russia and Tajikistan were historical partial exceptions but have since moved to full MMR vaccination.
Dr. Rajeev said one potential advantage of the new approach is the separation of vaccines into essential and optional categories.
He said this could give parents greater clarity about which vaccines are considered the highest priority and potentially help address some forms of vaccine hesitancy. The expert also pointed to US policy around childhood COVID-19 and influenza vaccines, saying that making these vaccines a shared decision between doctors and parents could be viewed as a progressive step.
© 2024 Bennett, Coleman & Company Limited